India · Delayed Price · Currency is INR Concord Biotech Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 saw a 12% revenue decline due to geopolitical and supply chain disruptions, but profitability remained resilient with a 35% EBITDA margin. Management expects FY 2027 growth to exceed historical rates, supported by new facilities, regulatory approvals, and operating leverage.
-
Q3 FY26 saw 14% revenue growth year-over-year, with API volumes driving performance and injectables poised for future growth. Margins were impacted by startup costs, but normalization is expected as new facilities scale. Cash position remains strong, supporting both organic and inorganic expansion.
-
Revenue declined 20% YoY in Q2 FY2026 due to regulatory and geopolitical delays, but management expects a strong H2 as deferred sales resume and new facilities ramp up. EBITDA margin, adjusted for startup costs, remained robust at 41%.
-
Q1 FY26 revenue declined 5% year-over-year to INR 204 crore due to sales lumpiness, with EBITDA and PAT impacted by startup costs at the new injectable facility. Formulation revenue grew 12%, API declined 10%, and the company advanced its US and India market presence, CDMO, and injectables ramp-up.
Fiscal Year 2025
-
Revenue grew 35% YoY in Q4 and 18% for FY25, with PAT up 21% and strong EBITDA margins. Strategic investments, new injectable capacity, and a robust product pipeline support long-term growth, while the CDMO business is set for expansion.
-
Revenue grew 1% YoY in Q3 FY25 and 10% for nine months, with strong formulation growth and stable margins. The company maintains a 25% CAGR target, expects a strong Q4, and is ramping up new facilities and product launches while remaining debt-free.
-
Q2 FY25 saw 18% YoY revenue and PAT growth, driven by strong formulation performance and steady API business. Margins remained robust despite a higher share of lower-margin formulations, and the company maintains a zero-debt position with significant cash reserves.
-
Q1 FY25 saw 11% revenue growth and 20% higher PBT (ex-JV), with strong formulation segment expansion and stable API margins. The injectable facility is set for Q4 FY25 launch, and long-term growth guidance remains unchanged.